Page 1 | Search Results | Blood | American Society of Hematology

1-5 of 5

Sort by

Sort Order Select

Journal Articles

Tyrosine Kinase Inhibitor-Mediated Apoptosis Is Potentiated by FasL and Increased with IFN-α in Chronic Myeloid Leukemia

Laurence Legros, MD, PhD, Nathalie Ebran, PhD, Jean-Michel Karsenti, MD, Faezeh Legrand, MD, PhD, Lionel Mannone, MD, Nicolas Mounier, MD, PhD, Henri Vinti, MD, Jill-Patrice Cassuto, MD, Pierre-Simon Rohrlich, MD, PhD, Anne-Odile Hueber, PhD

Blood (2012) 120 (21): 4428.

https://doi.org/10.1182/blood.V120.21.4428.4428

Published: 2012

Journal Articles

Immune modulation by Fas ligand reverse signaling: lymphocyte proliferation is attenuated by the intracellular Fas ligand domain

Blood (2011) 117 (2): 519–529.

https://doi.org/10.1182/blood-2010-07-292722

Published: 2011

Includes: Supplemental data

Journal Articles

Treatment of MDS with Excess Blasts by Bevacizumab Is Well Tolerated and Is Associated with a Decrease of VEGF Plasma Level.

Laurence Legros, Boranne Slama, Jean-Michel Karsenti, Norbert Vey, Shanti Natarajan-Ame, Eric Watel, Bruno Richard, Krimo Bouabdallah, Lionnel Mannone, Irit Touitou, Sebastien Huault, Jerome Durivault, Anne-Odile Hueber, Jean-Francois Michiels, Pierre Fenaux, Francois Dreyfus

Blood (2009) 114 (22): 2770.

https://doi.org/10.1182/blood.V114.22.2770.2770

Published: 2009

Journal Articles

Preliminary Results Concerning the Prognosis Value of Vascular Endothelial Growth Factor (VEGF) in Chronic Myeloid Leukemia Patients Treated with Imatinib Mesylate.

Laurence Legros, MD, PhD, Sebastien Huault, Francois-Xavier Mahon, MD PhD, Anne-Odile Hueber, PhD, Irit Touitou, Jill-Patrice Cassuto, MD, Joelle Guilhot, Claude Peudhomme, MD PhD

Blood (2006) 108 (11): 4763.

https://doi.org/10.1182/blood.V108.11.4763.4763

Published: 2006

Journal Articles

Fas ligand is localized to membrane rafts, where it displays increased cell death–inducing activity

Nathalie Cahuzac, Wiebke Baum, Vladimir Kirkin, Fabien Conchonaud, Laure Wawrezinieck, Didier Marguet, Ottmar Janssen, Martin Zörnig, Anne-Odile Hueber

Blood (2006) 107 (6): 2384–2391.

https://doi.org/10.1182/blood-2005-07-2883

Published: 2006

NARROW

Tyrosine Kinase Inhibitor-Mediated Apoptosis Is Potentiated by FasL and Increased with IFN-α in Chronic Myeloid Leukemia

Immune modulation by Fas ligand reverse signaling: lymphocyte proliferation is attenuated by the intracellular Fas ligand domain

Treatment of MDS with Excess Blasts by Bevacizumab Is Well Tolerated and Is Associated with a Decrease of VEGF Plasma Level.

Preliminary Results Concerning the Prognosis Value of Vascular Endothelial Growth Factor (VEGF) in Chronic Myeloid Leukemia Patients Treated with Imatinib Mesylate.

Fas ligand is localized to membrane rafts, where it displays increased cell death–inducing activity

Email alerts

ASH Publications

American Society of Hematology

Tyrosine Kinase Inhibitor-Mediated Apoptosis Is Potentiated by FasL and Increased with IFN-α in Chronic Myeloid Leukemia

Immune modulation by Fas ligand reverse signaling: lymphocyte proliferation is attenuated by the intracellular Fas ligand domain

Treatment of MDS with Excess Blasts by Bevacizumab Is Well Tolerated and Is Associated with a Decrease of VEGF Plasma Level.

Preliminary Results Concerning the Prognosis Value of Vascular Endothelial Growth Factor (VEGF) in Chronic Myeloid Leukemia Patients Treated with Imatinib Mesylate.

Fas ligand is localized to membrane rafts, where it displays increased cell death–inducing activity

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only